StockData

Brainsway vs Lensar

BWAY and LNSR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BWAY and LNSR compare

Brainsway grew revenue faster over the last twelve months (27.3% versus 3.3% for Lensar).

Lensar scores higher on the StockData Score (7 against 5 for Brainsway), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBWAYLNSR
Size and price
Market cap–$65.0M
Share price$10.11$5.29
Change, 1 year28.1%−48.4%
Change, 5 years155%−24.6%
Beta (5Y)–1.50
Employees129150
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score4 (better)2
Performance score02 (better)
Health score12 (better)
Dividend score00
Valuation
P/S–1.1×
P/B–4.4×
Fair value–$6.28
Margin of safety–15.8%
Growth
Revenue growth (TTM)27.3% (better)3.3%
Revenue growth, 5Y average18.8% (better)17.2%
EPS growth (TTM)260%–
Profitability
Gross margin75.4% (better)48.3%
Operating margin8.3% (better)−13.5%
Net margin–57.6%
Financial health
Debt / equity–0.25
Interest coverage2.0×–
Current ratio3.59 (better)2.39
Altman Z-score–−0.86
Piotroski F-score–3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions29.2%36.0%
Held by insiders25.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.